



Available online at <https://www.s-epub.in/>

Pharma Research

An International Peer Reviewed, Indexed Journal

10.62655/s-epub.2021.v13.i02.pp1-8

Status of Oral Chrono pharmaceuticals Drug Delivery System, Latest Technologies, and Hurdles

Ibrahim Aminu Shehu^{1*} Muhammad Kabir Musa²

Affiliation

¹(B. Pharm. MSc.Drug Design and Development) Department of Allied Health Sciences, Sharda University, Greater Noida, India.

²(B. Pharm. MSc Pharmaceuticals) Department of Pharmaceutical Sciences, Ahmadu Bello University, Zaria, Kaduna, Nigeria.

Article info

Published on: 22-11-2021
ISSN :0975-8216

Keywords:

homeostatic balance, circadian rhythm, chronotherapy, chronopharmaceuticals.

Abstract

Homeostatic theory, upon which conventional drug

condition of all biological activities remains constant over time. It was subsequently acknowledged in the field of logic that the concept of homeostasis in the body is never again obvious. Therefore, scientists are thinking about how to use circadian rhyming to create a novel kind of medicine administration called chronotherapeutics, which might lead to new forms of treatment called chronotherapy. However, state of the art and the challenges faced by chronotherapeutics published within the last two decades, in addition to reports and textbooks from the same time period. In conclusion, there is an excess of research into potential new medication delivery methods that could improve health outcomes via tailored treatment. Therefore, there must be massive investment in chronotherapy research. It is also necessary to pool all existing innovative drug delivery systems so that they can be improved over time and shared with regulatory agencies so that clinical trial pathways can be developed through collaboration between researchers and policymakers.

INTRODUCTION

A very wide variety of methods are included within the term "Drug Delivery" to introduce medicinal substances into the human system. Medicines used

to treat certain illnesses.(1)Of the several methods for administering medications, the oral route is by far the most common. However, by altering these

drug delivery systems to more sustainable and regulated ones, we may address the constraints of traditional dosage forms, such as poor patient compliance, repeated dosing, and fluctuations in the therapeutic variable range.(2)The traditional idea of homeostasis, which states that all biological activities remain consistent throughout time, was the foundation for the design of traditional drug delivery systems. The fact that illness symptoms and blood plasma concentration both exhibit circadian fluctuations across time was only realised a little while later. So, scientists have come up with a new way to administer drugs (chronotherapeutics) that will lead to new forms of treatment (chronotherapy) by using the idea of circadian rhythm. (4)More research is required to expand its uses to vaccines, producer-guided chronotheranostics, and disease chronoprevention.(5)

CHRONOTHERAPEUTICAL DRUG DOSAGE FORMS

Extensive research has been conducted over the last several decades on various equipment types with the aim of developing time-controlled paroral medication delivery systems.

First, a gadget that combines a tablet with a capsule: The medicine is released in three pulses via a new technology that uses a "tablet in capsule device" (65). The designation process has three steps: first, coating the hard gelatin capsule shell (#0) with Eudragit S100. Then, you prepare the first-pulse granules and second-pulse matrix tablets. Finally, you encapsulate all of the pulses in the coated hard gelatin capsule, which is called the "tablet in capsule system" (TICS). (6)The apparatus is made up of a water-soluble top, a capsule body that is impermeable, and two tablets that are multi-layered and enclosed in a water-soluble top. To fill the capsule and regulate the barrier layer, lactose is employed. Ethylcellulose (EC) is part of the waterproof capsule, and cross povidone makes up the quick release layer.

with lactose. The effectiveness of sodium alginate and hydrophobic polymethyl cellulose (HPMC) as modifying barriers was shown to be superior to that of carbopol and carboxymethylcellulose. (65)





Figure 1: A tablet in capsule device

1. **Core-in-cup tablet technology:** Efentakis et al. developed a drug delivery system based on core-in-cup technology. (7)The core-in-cup design where the medication containing dynamic center encompassed by an impermeable cup made of hydrophobic material that goes about as a hindrance and permits sedate discharge from a solitary uncovered surface. (8) An active sustained-release plate molded network center containing the dynamic fixing is pressure covered on the base just as an outline to shape a cup around the center. (9)The top layer contained a dissolvable polymer, for example, sodium carboxymethylcellulose, sodium alginate, and PEO. Upon contact with disintegration media, the top spread ingests liquid and swells making a hindrance between the disintegration media and the inward medication-containing center. The time taken for the swollen layer to dissolve decides the slack time. Once the top layer has disintegrated, drug release occurs.(7)



2. **Coated drug-core tablet matrix:** Lee et al. developed a hydroxypropylmethylcellulose tablet matrix comprising an inner drug core and an outer drug coating. The inner drug core was prepared using direct compression of the drug and polymer. The core was then coated with a drug containing aqueous-based polymeric Eudragit® RS30D dispersion. The tablet was able to provide a biphasic release profile with an initial zero-order release followed by a second phase of drug release.(10)




Figure 3: coated drug-core tablet matrix

3. **A bi-layered tablet:** A study by Karavas et al. involved the development of a bi-layered tablet that gave a slack stage followed by medicate discharge. The bi-layered tablet utilizes felodipine and PVP as a medication center and an HPMC/PVP mix encompassing the center. The mix of HPMC and PVP served to improve the mucoadhesive properties of the tablet. Upon introduction to disintegration media, the external layer broke down presenting the center to the gastric substance and in this way permitting drug discharge. Slack time was subject to the expanding/disintegration of the HPMC/PVP network. Fluctuating the proportion of the HPMC to PVP likewise influenced the slack time.(11)A quick/ slow-release system gives an underlying eruption of medication discharge followed by a consistent rate (in a perfect world) of discharge over a characterized period. (12)

CHRONOTHERAPEUTIC DRUG DELIVERY TECHNOLOGY

1. **CONTIN®:** Technology (Purdue Pharma, Pickering, Ontario, Canada), involving dynamic medicament and hydrophilic polymer followed by particular hydration with a polar solvent and absorption through a higher alcohol liquor. A molecular coordination complex-shaped between a cellulose polymer and a subbed alcoholic liquor, the product is a complex that could be used for controlled drug release. The complex product has a uniform porosity that might change. (13) This technology is used in the long-acting bronchodilator Uniphyll® (Theophylline).

2. **Chronotopic®:** Chronotopic® is a technology delivery system that contains a functioning medication loaded center covered with hydroxyl propyl methylcellulose (HPMC) polymer (a swellable hydrophilic). The HPMC

covering experiences polished rubbery progress when in contact with watery liquids. The dynamic medication is then discharged over the gel-layer by either dissemination or disintegration. The beginning of medication discharge and slack time are constrained by the thickness and consistency evaluation of the HPMC coat utilized during the formulation. (14)Moreover, the utilization of a gastro-resistant film onto the polymer-coated center of the system beats the fluctuation in gastric transit time and takes into consideration colon explicit drug discharge (15). The film permits the system to remain unchanged until arriving at the digestive tract where it in the end disintegrates and uncovered the HPMC layer to the intestinal liquid in this way permitting the system to be pH-responsive. The tablet matrix is set up right off the bat, grinding the medication with a scope of excipients, which is compared. A blend of HPMC and PEG arrangements is then spray coated onto the core and permitted to dry. From that point, a coating of Eudragit® is applied onto the external surface of the tablet lattice. (16)

3. **Pulsincaps®:** Pulsincaps® technology (Catalent Pharma Solutions, Somerset, New Jersey, USA) consists of a water-insoluble drug-loaded capsule. (17)The capsule is sealed with a swellable hydrogel plug comprising polymers such as the poly (methacrylates), hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinyl acetate, polyethylene oxide, saturated polyglycolic d-glycerides, glycerylmonooleate or pectin(18). The capsule is then coated with an enteric layer that dissolves after arriving at the small digestive tract where the polymeric attachment starts to grow to bring about a slack stage preceding medication discharge. (14)The attachment at that point grows

and is pushed outward to influence medicate release. The variety in measurements of the fitting and its point/profundity of inclusion into the case decides the slack time created preceding drug release.(19) Pulsincaps® technology has the versatility of allowing one or more mini-tablets, coated tablets, solutions, or multiple particulates to be stacked inside the container for the conveyance of medications in a chronotherapeutic way.(17)

4. CEFORM®: CEFORM® technology (Biovail Corporation, Mississauga, Ontario, Canada) involves the production of microspheres that are uniform in shape and size. The diameter of microspheres lies between 150–180 µm with a high drug-loading capacity that can be applicable in many drug delivery systems including capsules, suspensions, tablets, effervescent tablets and sachets.(20), (19), (21)the technology involves exposing biodegradable polymers or bioactive agents to a mixture of thermal gradients, mechanical forces, and flow-rates during processing. CEFORM® technology employed in the development of chronopharmaceutical Cardizem® LA which contains Diltiazem as an active pharmaceutical ingredient, the drug prescribes to be taken once daily(20)

5. TIMERx®: TIMERx® is a multipurpose hydrogel base control-release technology developed by Penwest Pharmaceuticals (Danbury, Connecticut, USA). It can be designed to convey different release kinetic (like zero-order, CR, pulsatile release et al.) simply be manipulation of molecular interaction. (22) TIMERx® delivers drug to gastrointestinal tract at programmed rate that coincide with circadian rhythm. (14)As the tablet moves along the gastrointestinal tract through the pylorus into the duodenum, the outer swellable coating undergoes erosion. After approximately 3.5hours, erosion of the coating is complete, exposing the drug-loaded core to the intestinal environment where drug is released. The inclusion of a surfactant into the drug-loaded core confers immediate drug release capabilities.(22)

6. OROS®: An OROS® osmotic pump patented by the DURECT Corporation (Cupertino, California, USA) that makes use of an osmotic mechanism to deliver the predetermined, controlled drug. The technology

involves three compartments namely, drug-loaded compartment, a push compartment, and semi-permeable membrane. The drug compartment comprised drug and polyethylene oxide (PEO) grated with a solution of polyvinyl pyrrolidone (PVP). The push compartment comprises PEO, hydroxypropylmethylcellulose (HPMC), sodium chloride and black ferric oxide granulated with HPMC. Both the drug compartment and the push compartment were later compressed into a bi-layered core. The entire core, or otherwise only the drug compartment, is sub-coated with a 95% hydroxyethylcellulose (HEC) and 5% poly(ethylene glycol) (PEG) solution that aids a drug-free interval of 2–5 hours. From there on, the sub-coated medication core is covered with a semi-permeable film including 60% cellulose acetic acid derivation, 35% hydroxypropyl cellulose (HPC) and 5% PEG. The hole is then penetrated into the external and inward core to connect the medication layer with the outside of the drug delivery system. Finally, the osmotic pump is dried for 96 hours to evacuate leftover dissolvable and a further 2 hours to take out any abundance moisture, drug release occurs due to the influx of fluid across the semi-permeable membrane into the push compartment. (23)

1. **CODAS®:** CODAS® Elan Corporation (Florida, USA) mass-produced multi particulate drug delivery system that delivers drugs in a controlled manner, bringing about a coincided release of circadian rhythms. (24) The technology consists of a drug-loaded core and a multilayered membrane surrounding the core containing water-soluble and water-insoluble polymers. If the product is exposed to water, the hydrophilic polymers dissolve and the drug diffuses through the pores present in the coating, while hydrophobic polymers act as a barrier and maintain the release of the drug (5). Verelan® PM (verapamil) was designed to be administered at bedtime, aiming to release the drug within 4–5 hours after ingestion to overcome the surge in morning blood pressure. (25)

1. **Diffucaps®:** Eurand Pharmaceuticals (Pennsylvania, USA) manufactured multiple particulate-based drug formulations capable of delivering the drug in coincidence with circadian rhythms. The medication layered onto a nonpartisan center that may include an inert particle such as sugar spheres, crystals or granules. The latent coating utilized to tie the medication particles to the inner core then the drug particles suspend in a 5–10% solution of a binder. Later the drug-loaded core is coated with a plasticized enteric-coated and from that point covered with a blend of water-insoluble and enteric polymers. (26)

1. **Egalet®:** Egalet® (Egalet a/s, Copenhagen, Denmark) technology uses erosion techniques. The technology encompasses an impermeable shell with two lag plugs enclosing a drug-loaded core. (27) The lag-phase is reliant on the composition as well as the length of the plugs. The impermeable shell comprises ethylcellulose and cetostearyl alcohol, whereas the plug consists of PEG and PEO. (27) The matrix is intended to disintegrate upon contact with the gastrointestinal liquid, however gastric liquid ought not to diffuse in the framework until the purpose of medication discharge. This decreases hydrolysis and luminal enzymatic action. In a perfect world, parity should exist between disintegration and dissemination with the end goal that the surface territory presented to the disintegration media is consistent guaranteeing. (27) The plan likewise takes into consideration that more than one medication can be consolidated in a solitary drug delivery system. Furthermore, by changing the outer fitting, distinctive discharge profiles might be acquired.

HURDLES IN CHRONOPHARMACEUTICAL **Current hurdles in chronopharmaceutical drug development are three, they includes:**

1. **Rhythmic biomaterial and system design:** Biomaterial and system design: the first obstacle approaches the designation of chronotherapeutics is the lack of ideal rhythmic biomaterials that are biocompatible, biodegradable and reversible that respond to specific biomarkers in ultra-fast rhythmic patterns in a biological system. (28) Efforts were made to overcome this hindrance for decades, but the latest technology introduced the designation of dosage forms that use chemical oscillators like PH oscillators as well as stimuli-sensitive polymers. Some studies reveal that chronotherapeutic administration of GHRH in the treatment of hypopituitary dwarfism is more effective. (5) In recent trends some of these biomarkers have been designed, they respond to external stimuli such as PH, temperature, light, electric field and ionic strength et al. this response resulted from changes in solubility, shape, surface characteristics, and formation of complex molecular self-assembly or sol - to -gel transition. (29) In the latest advancements, knowledge of microfabrication was employed to develop microchips based drug delivery systems. Robotic microchips forecast to be designed by co-entrapment of bioactive agents and biosensors into computer-controlled microchips and adoption nano microchips may optimize chronotherapy and stand as the lasting solution to this hurdle. (30)

1. **Rhythm engineering and modeling**

which they provide the necessity of taking the structures of 'cell division circle' into account for chronotherapy modeling.(32)Moreover, the Rössler model, three non-linear differential equations systems were proposed for chronotherapy modeling. Despite limited applications of the aforementioned models, they gave insight in modeling the direction of the rhythmic process.

(33)Concerning the effort attributes to elucidate the rhythmic processes in biological systems, the future challenge in this area includes engineering rhythmic responses in the biological system from the molecular response (rhythmic translation of mRNA to protein) to cellular, organ, tissue and, whole organ system. The protein synthesis process comprises transcription (transfer of genetic information from DNA to mRNA), translation (genetic codes of mRNA to protein) and their subsequent processing steps. To realize this goal a new mathematical, statistical and numerical analytical method is required to put in place. Though several unflinching efforts have been made to make it possible, amongst a Cell Circle Automation (CCA) model has been proposed, the model described transition through sequential phases of the cell cycle for chemotherapy. Besides the regulation of circadian, the Cell Circle Automation (CCA) can further be employed to investigate the role of different temporal patterns (a segment of signals that recur frequently) of drug administration.

. control infusion pump, it's logical to approximate the time dependent targeted drug tissue concentration —(1) (34) $C(t) = S(t) * R(t)$ _____ (1)

where 't' stand for a time, S, for drug delivery function and R for drug delivery rate. For extremely short drug delivery time t (say, $t = \epsilon$ second) in physiologically relevant media, the Dirac impulse -function ($\delta(t)$) could allow approximating S(t) before its use for C(t) estimation according to equation 2.

$$C\epsilon(t) = S(t) * \delta(t) = S(t) \quad \text{_____} (2) \quad (33)$$

However, due to wide-ranging of Importation and complex processes to be elucidated from molecular up to the system level, a lot of researches need to be conducted for future prospective.. (33)

1. Regulatory hurdles: Regulatory hurdles include pre and post-approval considerations. In the pre- approval phase, it is believed to have partial relation with first and second hurdles because it is somehow difficult to evidence chronotherapeutic advantage of **controlled-release** (CR) or modified release

(MR) formulations in clinically. Considering the control release nature of MR/CR formulations, they require specific considerations and regulation before conventional delivery formulations. (33)This is why pharmaceutical innovators use to educate the Federal Agency on the importance of putting these products under control. The US Code of Federal Regulations under 21 CFR 320.25 provides the bioavailability requirements for CR products.(35)The regulations of application with already approved IR formulation of the same drug ingredient or active moiety were covered under 21 CFR 314.54(36)Post-approval phase: Possibility of abusing these new drug products is the major obstacle encountered by manufacturers and regulators, fortunately, some solutions to counteract this problem were set aside. Both the regulator and manufacturers should consider all possible factors that could lead to drug -abuse-readyll so that proper risk management policies for implementation of post-approval,(37)as harnessed by FDA under it is initiated Programs called (MAP), which happen to be a strategy to allow approval of a drug to move on while making use of some restrictions.(38)

CONCLUSION

The search for novel drug delivery systems that can enhance the quality of life through individualized therapy is of high excess. Therefore, extensive research in the field of chronotherapy is a world necessity and the need to agglomerate all available innovative drug delivery systems that time to time can be improved and communicated to a regulatory agency to pave-way for clinical trials could provide synergy among researchers and policy formulator. However, in drug delivery in the biology of living species, time is a fundamental aspect that was long overlooked in drug design and delivery hence the need to conceptualize chronotherapy.

REFERENCES

- [1]. Research and development features of oral controlled release dosage formulations. author of the book Zhang G., Qiu Y. Handbook of controlled release technology in pharmaceuticals. Pages 465–503 in the 2005 edition, 1st Indian edition, New York: Replika publishing.
- [2]. The Matrix Tablet in Particular: An Introduction to Oral Sustained Release Tablets. *Gaurav Agarwal, *Shilpi Agarwal, *PK Karar, and *Shagun Goyal also contributed. Published in 2017 by the American Journal of Drug Delivery, Haryana, India.
- [3]. Chronobiology, drug-delivery, and chronotherapeutics. . "Adv Drug Deliv Rev" (Volume 59, 2007, pages 23–824) was written by Smolensky MH and Peppas NA.
- [4]. A synopsis of chronotherapeutics' development and regulatory initiatives. In 2016, the Journal of Therapeutic Innovation and Regulatory Sciences published an article by Muhammad Aamir and colleagues (Volume 50, pages 450–454). Youan edited the BBC. The field of chronopharmaceutics focuses on the science and technology of using biological rhythms to guide therapy and disease prevention. 2009, John Wiley & Sons, USA edition.
- [6]. Device for Variable Multipulse Delivery of Aceclofenac Based on Inulin: Optimisation and In Vivo Roentgenography. Vol. 14, pages. 736–747, published by AAPS PharmSciTech in 2013 in India by Puja Sharma and Kmala Pathak.
- [7]. An impermeable cup, a swellable top layer, and pulsatile release were designed and evaluated as a drug delivery device with a dry coating. Journal of Pharmaceutical Research, 2006, Volume 311, Pages 147–150 (Efentakis M, Koligliati S, Vlachou M. s.l.).
- [8] Fine-tuning and creation of a core-in-cup tablet for controlled theophylline release in artificial gastric and testicular fluid. 2000, Drug Development and Industrial Pharmacy, Vol. 26, pp. 767–772 (Dankwerts, MP). Incorporating both hydrophilic and hydrophobic polymers into a controlled release matrix [9]. Published in 1991 in Volume 68 of the International Journal of Pharmacy, by Al-Hmoud H, Efentakis M, and Choulis NH. The controlled release of a dual drug-loaded hydroxypropyl methylcellulose matrix tablet with polymeric coatings carrying the medication was described in reference [10]. Int. J. Pharm., 1999, 188:71–80, Lee BJ, Ryu SG, Cui JH, et al.
- [11] Coatings made of PVP/HPMC with nanodispersions as its active core allow for predictable pulsatile chronotherapeutics. The authors of this work are Karavas, Georgarakis, and Bkikiaris (1). Felodipine; International Journal of Pharmaceutical Sciences, 2006, Vol. 313, pp. 189–197.
- A Dual-Component Delivery System Containing Ibuprofen: The Compressed Matrix Core Tablet [12]. Volume 8, PORTUGAL: AAPS PharmSciTech, 2007, by Carla Martins Lopes, José M. Sousa Lobo, João F. Pinto, and Paulo C. Costa.
- [13]. Contin administration: factoring in dosage. Volume 78, Issue 7, Pages 768–773, Journal of Allergy and Clinical Immunology, 1986. Leslie S., et al.
- Time-specific medication delivery devices for chronotherapy [14]. In 2007, Patel GC, Patel JK, and Patel MM published.
- Drug delivery methods that are pulsatile [15] An strategy to regulated medication administration. Vol. 68, pp. 295–300, 2006: Indian Journal of Pharmaceutical Sciences, edited by Shweta A, Ali J, Alka A, Sanjula B, and Qureshi J. Oral delivery systems for time-and/or site-specific medication administration: in vitro and in vivo evaluations [16]. Publication: 2001, Journal of Control Release, Vol. 73, pp. 103–110; authors: Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, etc.
- Pulsatile drug delivery systems: a method for regulated medication administration [17]. Volume 63, Issue 3, pages 295–300, India: Indian Journal of Pharmaceutical Sciences, 2006, by Shweta A., Ali J., Alka A., Sanjula B., and Qureshi J. cited as [18]. Oral pulsatile delivery devices using hydrophilic polymers that may expand. Journal Article: Gazzaniga A, Palugan A, Foppoli A, Sangalli ME. Journal of Pharmacy and Biopharmaceutics in Europe, 2008, Vol. 68, pp. 11–18.
- [19]. Where we are now and where we're going in terms of medication delivery technology. Published in Pharmaceut Technol On-Line, Volume 25, pages 1–14, by Verma KV and Garg S., 2nd ed.
- [20]. Chronopharmaceutics: A new way to administer drugs that might be useful in the clinic or just a passing fad. Volume 98, Issue 3, pages 337–353, Journal of Control Release, 2004, Youan BBC.
- [21]. Development and assessment of pH-sensitive multi-particulate devices for the chronotherapeutic administration of dimenhydrochloride. Published in 2006, Volume 68, Pages 781–787, by Shivakumar HN, Suresh S, and Desai BG.
- [22]. Processing factors' effects on TIMERx's physical characteristics. European Journal of Pharmaceutical Sciences, 1996, Volume 4, written by Kelly ML, Tobyn MJ, and Staniforth JN etc. The number 23. Brief overview of SyncroDose products. Pennwest. 2007.

[24]. A study comparing the pharmacokinetics and pharmacodynamics of standard and slow-release metoprolol with single and several doses. The article was published in the 1980 edition of the *European Journal of Clinical Pharmacology* and was written by Kendall MJ, John VA, Quarterman CP, and Welling P. s.l. [25]. Cardiovascular chronotherapeutic agents pharmacology. Smith, DHG. Volume 14, Issue 3, 2001, *American Journal of Hypertension*, Washington, DC, USA. [26]. Comparing the bioavailability of verapamil PM, which is administered orally once nightly, with that of immediate-acting verapamil, which is dosed every eight hours, in a steady-state test. J. Butler, L. Prisant, and J. G. Devane. Volume 7, pages 345–351, *American Journal of Therapeutics*, 2000. [27]. Are the demands of chronotherapeutics too much for oral controlled drug delivery? Article published in the *Journal of Drug Delivery Technology* in 2006, volume 6, pages 1–5, by Washington N and Wilson CG. [28]. A therapeutically meaningful strategy to drug administration or a gimmick? That is the question posed by BB. Youan in the 2004 issue of the *Journal of Controlled Release* (Volume 98:, pp. 337–353), which is available online via PubMed. [29]. With the assistance of Borckmans P, Metens S, and DeKepper P, editors. The use of chemical and biochemical oscillators in autonomous rhythmic drug delivery systems was discussed by Siegel RA in a recent publication. *Chemical and Mechanical Unstable States in Reactive Materials*. Berlin, Heidelberg, New York: Springer Verlag, 2009, pages 175–201. [30]. published in *Nature Nanotechnol.* The art of molecular motor control. Volume 1, pages 25–35. Wesley RB, Feringa BL. 2006. The number 31. A. Methods for studying cellular rhythms using computational methods. Everything in nature. Volume 420, pages 238–245 of *Goldbeter* (2002, s.l. : [PubMed]). The number 32. A computerised infusion pump that allows for the adjustment of tissue tracer concentration during in vivo pharmacokinetic and pharmacodynamic investigations using Positron Emission Tomography. Two authors (Eriksson et al., 2008) published in *BMC Medical Physics*, volume 8, online. the number 33. The chronotherapeutic drug delivery system: challenges, potential, optimism, and hype. Publication: *Advance Drug Delivery and Reviews*, 2010, Volume 62, Pages 898–903, Youan, Bi-Botti C. 10, s.l. The number 34. An automated model of the cell cycle for studying the effects of time of day on the administration of anticancer drugs. Article published in 2007 in the *Journal of Advance Drug Delivery* by Altinok A, Levi F, and Goldbeter A, volume 29, pages 1036–1053.

21 CFR 320.25, 2009, FDA [35]. The protocol for measuring bioavailability in living organisms. s.l. : [Google Scholar] Citation list from 2009. The number 36. *Federal Register* 21 CFR 314.54. 2009. The steps to take when submitting an application to have a listed medicine modified or given a new indication; this requires studies. "Ref list" from Google Scholar, 2009, online. [37] Modern regulatory landscape presents unique obstacles for novel formulations of prohibited drugs. *Alcohol and Drug Depend. Supplement 1*. in 2006, Vol. 83, S63–7. McCormick, CG., s.l.: [PubMed] [Google Scholar]. New formulations of prohibited drugs face regulatory problems in today's climate [38]. *Alcohol and drug dependence*. CG., McCormick. In 2006, Vol. 83, S63–7. (online) [PubMed] [Google Scholar].